About this policy
During the 45-day comment period the DME MACs received a total of 301 comments. Two hundred and nine (209) from Optune ® users and/or caregivers, 80 from treating practitioners/researchers, 9 comments from 5 advocacy groups, 1 from a clinical society, 1 from the manufacturer and 1 from a consultant. Introduction to Responses The DME MACs appreciate the comments received from stakeholders during the open comment period on the proposed Tumor Treatment Field Therapy (TTFT) Local Coverage Determination (LCD). Pursuant to the CMS Program Integrity Manual (CMS Pub. 100-08) Chapter 13: In conducting a review, MACs shall use the available evidence of general acceptance by the medical community, such as published original research in peer-reviewed medical journals, systematic reviews and meta-analyses, evidence-based consensus statements and clinical guidelines. Accordingly, the final policy and our response to comments are based on the best currently available published clinical evidence, in order to afford the most optimal opportunity for success in Medicare-eligible beneficiaries with newly diagnosed Glioblastoma Multiforme (GBM).
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.